Leaños-Miranda Alfredo, Campos-Galicia Inova, Berumen-Lechuga María Guadalupe, Molina-Pérez Carlos José, García-Paleta Yolanda, Isordia-Salas Irma, Ramírez-Valenzuela Karla Leticia
From the Research Unit in Reproductive Medicine and Toco-Surgery Service, Unidad Médica de Alta Especialidad-Hospital de Ginecología y Obstetricia "Luis Castelazo Ayala," Instituto Mexicano del Seguro Social (IMSS), and the Research Unit in Thrombosis, Hemostasia and Atherogenesis, H.G.R. No. 1 "Dr. Carlos Mac Gregor Sánchez Navarro," IMSS.A. Leaños-Miranda, MD, DSc; I. Campos-Galicia, MD; M.G. Berumen-Lechuga, MD; C.J. Molina-Pérez, MD; Y. García-Paleta, QBP, Research Unit in Reproductive Medicine, Unidad Médica de Alta Especialidad-Hospital de Ginecología y Obstetricia "Luis Castelazo Ayala", IMSS; I. Isordia-Salas, MD, PhD, Research Unit in Thrombosis, Hemostasia and Atherogenesis, H.G.R. No. 1 "Dr. Carlos Mac Gregor Sánchez Navarro," IMSS; K.L. Ramírez-Valenzuela, MD, MSc, Toco-Surgery Service, Unidad Médica de Alta Especialidad-Hospital de Ginecología y Obstetricia "Luis Castelazo Ayala," IMSS.
J Rheumatol. 2015 Jul;42(7):1141-9. doi: 10.3899/jrheum.141571. Epub 2015 May 15.
To investigate whether angiogenic factors are associated with risk of developing preeclampsia in pregnant women with systemic lupus erythematosus (SLE).
We performed a nested case-control study within a cohort of SLE women with singleton pregnancies. The study included 42 patients with SLE who eventually developed preeclampsia and 75 normal SLE pregnancies. Serum samples were collected at 4-week intervals (from weeks 12 to 36). Serum samples were analyzed for soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and soluble endoglin (sEng).
Women destined to develop preeclampsia had lower PlGF levels and higher sFlt-1 and sEng levels, and a higher sFlt-1/PlGF ratio than normal pregnancies. These changes became significant at 12 weeks in patients destined to develop either early onset (< 34 weeks, p ≤ 0.003) or late-onset preeclampsia (≥ 34 weeks, p ≤ 0.02). The risk to develop preeclampsia was higher among patients with PlGF concentration values in the lowest quartile or with sFlt-1 and sEng levels, and sFlt-1/PlGF ratio, in the highest quartile of the normal SLE pregnancies distribution. The OR were higher and appeared earlier in patients destined to develop early onset preeclampsia (OR ≥ 16.2, from Week 12 onward) than in patients who presented preeclampsia later (OR ≥ 8.9, from Week 24 onward).
Changes in circulating concentrations of sFlt-1, PlGF, sEng, and the sFlt-1/PlGF ratio precede the onset of preeclampsia in SLE pregnancies. The risk profile of circulating angiogenic factors for developing preeclampsia distinctly evolves depending on whether this condition is manifested earlier or later.
探讨血管生成因子是否与系统性红斑狼疮(SLE)孕妇发生子痫前期的风险相关。
我们在一组单胎妊娠的SLE女性队列中进行了一项巢式病例对照研究。该研究纳入了42例最终发生子痫前期的SLE患者和75例正常SLE妊娠者。每隔4周(从第12周到第36周)采集血清样本。分析血清样本中的可溶性fms样酪氨酸激酶-1(sFlt-1)、胎盘生长因子(PlGF)和可溶性内皮糖蛋白(sEng)。
注定要发生子痫前期的女性,其PlGF水平较低,sFlt-1和sEng水平较高,且sFlt-1/PlGF比值高于正常妊娠。这些变化在注定要发生早发型(<34周,p≤0.003)或晚发型子痫前期(≥34周,p≤0.02)的患者中,在第12周时变得显著。在正常SLE妊娠分布中,PlGF浓度值处于最低四分位数或sFlt-1、sEng水平以及sFlt-1/PlGF比值处于最高四分位数的患者发生子痫前期的风险更高。与晚发型子痫前期患者(从第24周起,OR≥8.9)相比,注定要发生早发型子痫前期的患者(从第12周起,OR≥16.2)的OR更高且出现更早。
sFlt-1、PlGF、sEng的循环浓度变化以及sFlt-1/PlGF比值在SLE妊娠子痫前期发作之前就已出现。循环血管生成因子发生子痫前期的风险特征根据该病症出现的早晚而明显不同。